| Stereochemistry | ABSOLUTE |
| Molecular Formula | C10H10FNO2.ClH |
| Molecular Weight | 231.651 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.FC1=CC=CC2=C1O[C@H]3CNC[C@@H]3O2
InChI
InChIKey=JNYKORXHNIRXSA-OZZZDHQUSA-N
InChI=1S/C10H10FNO2.ClH/c11-6-2-1-3-7-10(6)14-9-5-12-4-8(9)13-7;/h1-3,8-9,12H,4-5H2;1H/t8-,9-;/m0./s1
| Molecular Formula | C10H10FNO2 |
| Molecular Weight | 195.1903 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Fluparoxan (GR50360A) is a potent α2-adrenergic receptor antagonist used in the treatment of central neurodegenerative diseases, depression, the improvement of cognitive dysfunction in schizophrenia and in models of Alzheimer's disease. Fluparoxan was undergoing phase III trials as an antidepressant, but this development was also discontinued because of poor efficacy.
